AtriCure (NASDAQ:ATRC) announced its quarterly earnings on Tuesday, revealing a surprising performance with earnings per share (EPS) of $0.06. This result exceeded analysts’ expectations, which had forecasted a loss of $0.04 EPS, marking a significant positive variance of $0.10, according to FiscalAI.
The medical device company reported revenues of $140.50 million for the quarter, aligning perfectly with consensus estimates. This figure reflects a 13.1% increase compared to the same period last year, when AtriCure recorded a loss of $0.33 EPS. In addition, the company reported a negative return on equity of 2.54% and a net margin of 5.55%.
AtriCure’s Stock Performance Overview
On Wednesday, AtriCure’s stock opened at $32.97. The company maintains a current ratio of 3.87, a quick ratio of 2.85, and a debt-to-equity ratio of 0.15. With a market capitalization of $1.64 billion, its price-to-earnings (P/E) ratio stands at -54.05. The stock has seen fluctuations over the past year, with a low of $28.29 and a high of $43.18.
In recent trading activity, AtriCure’s stock demonstrated volatility, supported by a 50-day moving average price of $38.77 and a 200-day moving average price of $36.80. An analysis of insider trading revealed that Justin J. Noznesky, an insider, sold 5,166 shares on November 26, receiving approximately $192,640.14. Post-sale, he retains 78,798 shares valued at about $2.94 million, indicating a 6.15% decrease in his ownership.
Similarly, Director Maggie Yuen sold 3,000 shares on November 21 for $107,160. Following this transaction, she owns 11,371 shares valued at roughly $406,172. These transactions were disclosed in filings with the Securities and Exchange Commission (SEC).
Institutional Investment Trends
Recent activity among institutional investors further illustrates AtriCure’s market dynamics. AQR Capital Management LLC increased its stake in AtriCure by 1.0%, now holding 83,685 shares worth approximately $2.7 million. Meanwhile, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings by 4.6%, acquiring an additional 1,230 shares.
Goldman Sachs Group Inc. also expanded its position in AtriCure by 1.0%, owning 862,668 shares valued at about $27.83 million after acquiring 8,956 shares. Notably, Jane Street Group LLC significantly increased its stake by 658.3%, now holding 100,853 shares after purchasing an additional 87,553 shares.
Currently, institutional investors and hedge funds control 99.11% of AtriCure’s stock, indicating strong institutional confidence in the company.
AtriCure, based in Mason, Ohio, specializes in innovative therapies for atrial fibrillation (AF) and related conditions. Founded in 2000, it has established itself as a leader in surgical ablation devices that address the errant electrical pathways causing AF. The company’s flagship products include the Synergy Surgical Ablation System and the cryoICE Cryoablation System, both designed to enhance patient outcomes during cardiac procedures.
As AtriCure continues to navigate the complexities of the medical device market, its recent earnings report signals positive growth potential and robust investor interest.
